Cerevance
Its proprietary NETSseq platform identifies groundbreaking treatment targets with precision. Cerevance’s team of world-leading scientists and drug developers use NETSseq and advanced machine learning to identify undiscovered profiles of gene expressions in select cells.
With a collection of over 14,000 human brain tissue samples, the company can generate an impressive pipeline of next-generation CNS treatments to transform patient quality of life.
Cerevance recently added $47m to its Series B-1 round extension to advance a robust clinical pipeline. The funding accelerates key programmes and advances clinical trials in multiple disease areas and will also support the upcoming Phase 3 clinical trial for CVN424, a first-in-class non-dopamine therapy for patients with Parkinson’s disease. It also enables the advancement of a pipeline of novel treatments for other CNS disorders, including frontotemporal dementia.
In 2024, Cerevance celebrated its first milestone in a research collaboration with Merck (MSD) in a mission to identify novel therapeutic targets for Alzheimer’s. The achievement resulted in an undisclosed sum from Merck.
